Skip to main content
. Author manuscript; available in PMC: 2020 Dec 10.
Published in final edited form as: Clin Ther. 2018 Aug 10;40(8):1282–1298. doi: 10.1016/j.clinthera.2018.07.006

Table II.

Antiherpesviral agents underdevelopment.

Drug Antiviral Activity Mechanism of Action Study Population/Stage of Study
Brincidofovir All herpesviruses Nucleotide analogue–polymerase inhibitor Phase III study reported increased CMV disease possibly related to increased GVHD.* CMV trials suspended; adenovirus trials ongoing. IV preparation in development
Maribavir CMV Competitive inhibitor of ATP binding to UL97 protein kinase inhibition of viral encapsidation and nuclear egress of viral particles Phase III study failed to show efficacy for suppressive therapy to prevent disease post-BMT.122 Ongoing Phase III trial to determine efficacy for treatment of resistant CMV disease in transplant recipients (NCT02931539)
Valomaciclovir HSV
VZV
EBV
Nucleoside analogue–polymerase inhibitor Completed small, randomized, placebo-controlled trial to assess clinical activity for infectious mononucleosis due to EBV. Phase IIb trial for treatment of zoster in adults underway123
N-Methanocarbathymidine HSV
EBV
KSHV
Nucleoside analogue–polymerase inhibitor Demonstrated superior efficacy in animal models of HSV infection.127,128 Ongoing Phase I trial in healthy volunteers (NCT02778386)
Pritelivir (AIC316) HSV Helicase-primase inhibitor In vitro potency superior to acyclovir and effective in animal models of HSV infection.129,130 Completed Phase II trial for treatment of genital herpes.132 Ongoing open-label trial to assess efficacy and safety for treatment of acyclovir-resistant mucocutaneous HSV infection in immunocompromised hosts (NCT03073967)
Amenamevir (ASP2151) HSV
VZV
Helicase-primase inhibitor Approved for treatment of zoster in Japan in September 2017. In the United States, Phase I trial halted due to safety concerns; no further data available

ATP = adenosine triphosphate; BMT=bone marrow transplantation; CMV= cytomegalovirus; EBV= Epstein-Barr virus; GVHD = graft-versus-host disease; HSV= herpes simplex virus; IV = intravenous; KSHV= Kaposi’s sarcoma-associated herpesvirus; VZV = varicella zoster virus.

*

Source: Marty FM, Winston DJ, Chemaly RF, Boeckh M, Mullane KM, et al. 2016. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial [abstract]. Biol Blood Marrow Transplant 22: S23.